ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0035

Bromodomain Protein-regulated Stress Response in Rheumatoid Arthritis Synovial Fibroblasts

Tanja Seifritz1, Thomas Züllig1, Larissa Moser1, Oliver Distler2, Caroline Ospelt1 and Kerstin Klein3, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, 3Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland

Meeting: ACR Convergence 2021

Keywords: Fibroblasts, Synovial, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: RA – Etiology & Pathogenesis Poster (0011–0045)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Hypoxia and subsequent oxidative stress are early events in the RA joint and contribute to the activation of synovial fibroblasts (SF). Small molecule inhibitors targeting the members of the bromodomain and extra-terminal (BET) protein family (BRD2, BRD3, BRD4) have anti-inflammatory properties in RA. Here we analyzed the potential of BET inhibitors in regulating stress response pathways in RA SF.

Methods: SF were obtained from shoulder and hand joints of RA patients undergoing joint replacement surgery. We mimicked hypoxic conditions by treatment of SF with dimethyloxalylglycine (DMOG; 0.5 mM, 24 h). Stabilization of HIF1α and GLUT1 protein expression were assessed by Western blotting. Oxidative stress was induced by treatment of SF with 4-hydroxynonenal (4-HNE; 5 µM, 48h), a lipid peroxidation product present in synovial fluids, and TNF (10 ng/ml, 48h). Experiments were performed in absence and presence of the pan-BET inhibitor I-BET151 (1 µM). The expression of hypoxic response (VEGFA, PDK1, GLUT1, HK2) and oxidative stress response genes (CAT, GPX1, SOD2, HMOX1) was measured by Real-time PCR (n=7-10). Autophagy was assessed by Western blotting using LC3B-II as an autophagy marker (n=7).

Results: Treatment of SF with DMOG stabilized HIF1α protein. I-BET treatment suppressed the DMOG-induced expression of the hypoxic response genes VEGFA, PDK1, GLUT1 and HK2 (Figure 1A). Hypoxic conditions induced the GLUT1 protein expression by 101.8-fold (± 108.2-fold), which was suppressed by 62.2% (± 32.1%) in presence of I-BET (p< 0.05). TNF treatment induced the expression of all measured stress response genes. Oxidative stress further induced the TNF-induced expression of VEGFA, PDK1, GLUT1, HK2 and CAT (Figure 1B). In contrast to results obtained under hypoxic conditions, I-BET treatment further increased the expression of hypoxia response genes under oxidative stress conditions. We have detected similarities and differences regarding the BET-meditated regulation of oxidative stress response genes under different stress conditions. I-BET increased basal HMOX1 and CAT expression in all conditions, and suppressed GPX1 expression under hypoxia and oxidative stress. In contrast, BET inhibition decreased the expression of SOD2 only during oxidative stress but not under hypoxia. I-BET further increased the expression of HMOX1 during oxidative stress, but suppressed the expression of HMOX1 during hypoxia. I-BET induced the accumulation of LC3B-II protein by 2.7 (± 1.4)-fold, which was further increased to 4.5 (± 2.9)-fold in presence of DMOG (p< 0.05). Oxidative stress conditions did not further induce the I-BET-induced expression of LC3B-II.

Conclusion: BET protein inhibition affects stress-response target genes in a stimulus-dependent manner. Our data suggest that hypoxia and oxidative stress conditions regulate individual stress response genes via distinct enhancers. Furthermore, we have identified BET proteins as regulators of autophagy.

Figure 1: Expression of stress response genes in synovial fibroblasts after treatment with A. DMOG +/- TNF and B. TNF +/- 4-HNE in absence and presence of the bromodomain inhibitor I-BET.


Disclosures: T. Seifritz, None; T. Züllig, None; L. Moser, None; O. Distler, AbbVie, 12, Project scoring fee for Rheumatology Grant, Amgen, 2, Eli Lilly, 2, Pfizer Inc, 2; C. Ospelt, Novartis Foundation for Biomedical Research, 5; K. Klein, Novartis Foundation, 5.

To cite this abstract in AMA style:

Seifritz T, Züllig T, Moser L, Distler O, Ospelt C, Klein K. Bromodomain Protein-regulated Stress Response in Rheumatoid Arthritis Synovial Fibroblasts [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/bromodomain-protein-regulated-stress-response-in-rheumatoid-arthritis-synovial-fibroblasts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bromodomain-protein-regulated-stress-response-in-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology